What is the Difference Between MGUS and Multiple Myeloma?
🆚 Go to Comparative Table 🆚MGUS (Monoclonal Gammopathy of Undetermined Significance) and Multiple Myeloma are both conditions affecting plasma cells, but they differ in their severity and potential for progression.
MGUS:
- A noncancerous condition characterized by abnormal plasma cells.
- More common in older adults and can sometimes precede Multiple Myeloma.
- People with MGUS often have no symptoms and are often diagnosed during a routine blood test.
- About 20% of patients with MGUS progress to active Multiple Myeloma.
- No treatment is required unless patients choose to participate in a clinical trial.
Multiple Myeloma:
- A type of blood cancer affecting plasma cells.
- Affects the production of healthy white blood cells, impacting the immune system.
- Can also affect other areas of the body, such as bones, kidneys, and nerves.
- Symptoms may include infection, weight loss, muscle weakness, confusion, fatigue, digestive issues, osteoporosis, broken bones, shortness of breath, dizziness, and constipation.
- A variety of tests can diagnose Multiple Myeloma, including blood counts, imaging, and bone marrow biopsy.
In summary, MGUS is a noncancerous condition with no symptoms, while Multiple Myeloma is a type of blood cancer with symptoms and potential complications. About 1% of patients with MGUS progress to Multiple Myeloma each year. Although no treatment is required for MGUS, it is essential to monitor patients with MGUS to ensure it does not progress to Multiple Myeloma.
Comparative Table: MGUS vs Multiple Myeloma
Here is a table comparing the differences between MGUS (Monoclonal Gammopathy of Undetermined Significance) and Multiple Myeloma:
Feature | MGUS | Multiple Myeloma |
---|---|---|
Definition | A noncancerous condition affecting the plasma cells in the bone marrow | A cancerous condition affecting the plasma cells in the bone marrow |
Symptoms | Usually no symptoms, often diagnosed during routine blood tests | Symptoms may include infection, weight loss, muscle weakness, confusion, fatigue, digestive issues, osteoporosis, broken bones, shortness of breath, dizziness, and constipation |
Risk Factors | Older age, male sex, black race, and family history of MGUS | Increasing age, male sex, black race, family history of multiple myeloma, and personal history of MGUS |
Progression Risk | 20% of patients with MGUS progress to active myeloma | - |
Diagnostic Tests | Blood tests, bone marrow biopsy, imaging tests (PET scans, CT scans, bone marrow X-rays, and MRI scans) | Blood tests, bone marrow biopsy, imaging tests (PET scans, CT scans, bone marrow X-rays, and MRI scans) |
Treatment | Monitored by a hematologist/oncologist, as it is considered a precursor to multiple myeloma | Treatments include targeted therapy, immunotherapy, chemotherapy, corticosteroids, bone marrow transplant, and radiation therapy |
MGUS is a benign condition characterized by a low level of monoclonal protein and abnormal plasma cells in the bone marrow, with no indicators of active disease. On the other hand, multiple myeloma is a cancerous condition that affects the plasma cells of the bone marrow, causing various symptoms and often affecting other areas of the body, such as the immune system, bones, kidneys, and nerves.
- Myeloma vs Multiple Myeloma
- Leukemia vs Multiple Myeloma
- Smoldering Myeloma vs Multiple Myeloma
- Myeloma vs Lymphoma
- CLL vs Multiple Myeloma
- Amyloidosis vs Multiple Myeloma
- Multiple Myeloma vs Waldenstrom’s Macroglobulinemia
- Leukemia vs Myeloma
- Myeloproliferative vs Myelodysplastic
- MDS vs Leukemia
- Muscular Dystrophy vs Myasthenia Gravis
- Guillain Barre Syndrome vs Myasthenia Gravis
- Myeloblast vs Lymphoblast
- Leukemia vs Lymphoma
- Multiple Sclerosis vs Systemic Sclerosis
- Transverse Myelitis vs Guillain Barre Syndrome
- Lymphocytic Leukemia vs Lymphoma
- Promyelocyte vs Myelocyte
- Bone Cancer vs Leukemia